Meta-analysis of the value of exosomal miRNA for the diagnosis of chronic kidney disease

doi:10.12307/2023.286

Abstract

Abstract: OBJECTIVE: To evaluate the diagnostic significance of exosomal miRNA for chronic kidney disease by meta-analysis.
METHODS: The clinical research on the diagnosis of chronic kidney disease by exosomal miRNA published from the establishment of Wanfang, CNKI, China Biology Medicine disc, VIP, Web of Science, Cochrane Library, PubMed, and Embase to May 2022 was searched by computer. After screening and extracting the data, the quality of the article was evaluated through the quality assessment of diagnostic accuracy studies-2 in Review Manager 5.3. Meta-disc 1.4 software was used to analyze the heterogeneity of threshold/non threshold effects included in the literature, and calculate sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, area under the curve, and diagnostic odds ratio. StataMP 16.0 software was used to analyze sensitivity, heterogeneity, and publication bias.
RESULTS: A total of six articles were included. Meta-analysis results exhibited that the Spearman correlation coefficient was -0.603 (P=0.038 < 0.05), and there was a threshold effect in this study. The diagnostic odds ratio Cochran-Q was 67.85 (P < 0.01), indicating that there was heterogeneity caused by non threshold effect in this study, and the effect size was pooled by using random effect model. The pooled sensitivity was 0.81 (0.78-0.84), pooled specificity 0.81(0.76-0.85), pooled positive likelihood ratio 3.32(1.98-5.57), pooled negative likelihood ratio 0.30(0.19-0.48), pooled area under the curve=0.840 1, Q-index=0.771 9; pooled diagnostic odds ratio was 12.20(4.74-31.42). Publication bias was present at this study, and there was one inclusion with strong sensitivity (P=0.01 < 0.05).
CONCLUSION: Exosomal miRNA expression levels have great value and significance for the diagnosis of chronic kidney disease. However, due to the small number and heterogeneity of included studies, more clinical studies are needed to find out the optimal exosomal miRNA for diagnosing chronic kidney disease.

Key words: exosome, chronic kidney disease, miRNA, meta-analysis, diagnosis

CLC Number:

Chen Guanting, Zhang Linqi, Li Qingru. Meta-analysis of the value of exosomal miRNA for the diagnosis of chronic kidney disease[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(6): 970-976.

Figures/Tables 7

References

[1] Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19-62.
[2] NATIONAL KIDNEY FOUNDATION. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 (2 Suppl 1):S1-S266.
[3] EKNOYAN G, LAMEIRE N, ECKARDT KU, et al. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Foreword. Kidney international supplements. 2013;3(1):1-150.
[4] LEVEY AS, INKER LA, CORESH J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014;63(5):820-834.
[5] WASUNG ME, CHAWLA LS, MADERO M. Biomarkers of renal function, which and when? Clin Chim Acta. 2015;438:350-357.
[6] 朱梦梅,林佳莉,王楚棋,等.治疗性外泌体的研究进展[J].药学学报,2022, 57(3):627-637.
[7] PARK SJ, KIM JM, KIM J, et al. Molecular mechanisms of biogenesis of apoptotic exosome-like vesicles and their roles as damage-associated molecular patterns. Proc Natl Acad Sci U S A. 2018;115(50): E11721-E11730.
[8] KALLURI R, LEBLEU VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
[9] BARILE L, VASSALLI G. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017;174:63-78.
[10] 邢昊楠,陆梅,刘瑛琪,等.基于外泌体的抗肿瘤药物靶向递送的研究进展[J].药学学报,2022,57(1):150-158, 277.
[11] HARRILL AH, SANDERS AP. Urinary MicroRNAs in Environmental Health: Biomarkers of Emergent Kidney Injury and Disease. Curr Environ Health Rep. 2020;7(2): 101-108.
[12] LV W, FAN F, WANG Y, et al. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiol Genomics. 2018;50(1):20-34.
[13] ICHII O, HORINO T. MicroRNAs associated with the development of kidney diseases in humans and animals. J Toxicol Pathol. 2018;31(1):23-34.
[14] KATARIA Y. Epidemiology of acute kidney injury in critically ill children and young adults. Ann Clin Biochem. 2017;54(3):416.
[15] RAMACHANDRAN K, SAIKUMAR J, BIJOL V, et al. Human miRNome profiling identifies microRNAs differentially present in the urine after kidney injury. Clin Chem. 2013; 59(12):1742-1752.
[16] YU Y, BAI F, QIN N, et al. Non-Proximal Renal Tubule-Derived Urinary Exosomal miR-200b as a Biomarker of Renal Fibrosis. Nephron. 2018;139(3):269-282.
[17] LV CY, DING WJ, WANG YL, et al. A PEG-based method for the isolation of urinary exosomes and its application in renal fibrosis diagnostics using cargo miR-29c and miR-21 analysis. Int Urol Nephrol. 2018;50(5):973-982.
[18] BERINGER PM, HIDAYAT L, HEED A, et al. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J Cyst Fibros. 2009;8(1):19-25.
[19] SOLÉ C, CORTÉS-HERNÁNDEZ J, FELIP ML, et al. miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. Nephrol Dial Transplant. 2015;30(9): 1488-1496.
[20] LV LL, CAO YH, NI HF, et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol Renal Physiol. 2013;305(8):F1220-1227.
[21] 陈笑,石嘉琪,聂安琪,等.外泌体miR-93-5p在慢性肾脏病患者中的表达及临床意义[J].中华肾脏病杂志,2021,37(10): 835-838.
[22] BELTRAMI C, CLAYTON A, NEWBURY LJ, et al. Stabilization of Urinary MicroRNAs by Association with Exosomes and Argonaute 2 Protein. Noncoding RNA. 2015;1(2):151-166.
[23] WHITING PF, RUTJES AW, WESTWOOD ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536.
[24] ZAMORA J, ABRAIRA V, MURIEL A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.
[25] BOSTON RC, SUMNER AE. STATA: a statistical analysis system for examining biomedical data. Adv Exp Med Biol. 2003; 537:353-369.
[26] 罗艳,胡桂英. 2型糖尿病肾病患者尿液外泌体中miRNA的表达谱分析研究[J]. 检验医学与临床,2017,14(9):1271-1274.
[27] NEAL CS, MICHAEL MZ, PIMLOTT LK, et al. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant. 2011;26(11):3794-3802.
[28] ZANG J, MAXWELL AP, SIMPSON DA, et al. Differential Expression of Urinary Exosomal MicroRNAs miR-21-5p and miR-30b-5p in Individuals with Diabetic Kidney Disease. Sci Rep. 2019;9(1):10900.
[29] KUMARI M, MOHAN A, ECELBARGER CM, et al. Corrigendum: miR-451 Loaded Exosomes Are Released by the Renal Cells in Response to Injury and Associated With Reduced Kidney Function in Human. Front Physiol. 2020;11:844.
[30] ZHANG L, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815-822.
[31] 谢院生,李清刚.肾脏病学临床研究新进展[J].中国中西医结合肾病杂志,2020, 21(6):471-473.
[32] 崔帅帅,杨晓红. miRNA在骨髓间充质干细胞自我更新、多向分化及命运和功能调控中的作用[J].中国组织工程研究, 2022,26(1):101-105.
[33] FICHTLSCHERER S, DE ROSA S, FOX H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010; 107(5):677-684.
[34] GANTIER MP, MCCOY CE, RUSINOVA I, et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res. 2011;39(13): 5692-5703.
[35] 季康寿,杨茗茜,陈文娜,等.外泌体miRNA与中医理论关联及在冠心病中的机制研究进展[J].中华中医药学刊, 2021, 39(5):48-52.
[36] 鲍博艺,李卫萍.外泌体miRNA在急性心肌梗死中的研究进展[J].首都医科大学学报,2022,43(2):199-204.
[37] NIK MOHAMED KAMAL NNSB, SHAHIDAN WNS. Non-Exosomal and Exosomal Circulatory MicroRNAs: Which Are More Valid as Biomarkers. Front Pharmacol. 2020; 10:1500.
[38] MANIER S, LIU CJ, AVET-LOISEAU H, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017; 129(17):2429-2436.
[39] SHAO L, ZHANG Y, LAN B, et al. MiRNA-Sequence Indicates That Mesenchymal Stem Cells and Exosomes Have Similar Mechanism to Enhance Cardiac Repair. Biomed Res Int. 2017;2017:4150705.
[40] 宋现静,吕文山.miR-16-5p下调ACE对高糖作用的肾小管上皮细胞增殖、凋亡的影响[J].中国老年学杂志,2021,41(9): 1908-1913.
[41] 郭汉城,丘昭文,凌毅生,等.人血白蛋白对近端肾小管上皮细胞ACE2表达的影响[J].中国病理生理杂志,2009, 25(10):2050-2052.
[42] MCCLELLAND AD, HERMAN-EDELSTEIN M, KOMERS R, et al. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci (Lond). 2015;129(12):1237-1249.
[43] 朱柄铭,陈文璟,苏运钦,等.血清miR-21在糖尿病肾病中的诊断价值.中国病理生理杂志,2013,29(12):2160-2166.
[44] 王彦哲,王筱霞,汪年松.miR-30b/Snail调控糖尿病肾病肾小管上皮细胞EMT[J].中国中西医结合肾病杂志,2017,18(4): 288-291,377-378.
[45] 王婷,刘宗明.lncRNA XIST靶向miR-30b-5p调控高糖条件下肾小管上皮细胞损伤的机制[J].中国老年学杂志,2022, 42(2):438-442.